A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
NCT ID: NCT03893682
Last Updated: 2025-03-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
36 participants
INTERVENTIONAL
2019-04-30
2024-05-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma
NCT00396864
Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL
NCT05360238
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
NCT01994382
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT06859008
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
NCT00131937
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose Escalation and Expansion
CG-806 will be given orally in ascending doses in patients with relapsed or refractory CLL/SLL or Non-Hodgkin's Lymphomas (escalation cohort), until the maximum tolerated dose or recommended dose is reached. Followed by up to 100 patients enrolled in the expansion cohort at the recommended dose.
CG-806
CG-806 will be given orally in ascending doses starting at 150 mg PO BID until the maximum tolerated dose or recommended dose is reached.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CG-806
CG-806 will be given orally in ascending doses starting at 150 mg PO BID until the maximum tolerated dose or recommended dose is reached.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Life expectancy of at least 2 months
* ECOG Performance Status ≤ 2
* Patients must be able to swallow capsules
* Adequate hematologic parameters, unless cytopenias are disease caused
* Adequate renal, liver and cardiac function parameters
Exclusion Criteria
* Uncontrolled leptomeningeal disease, auto-immune hemolytic anemia and uncontrolled and clinical significant disease related metabolic disorder
* Clinically significant intravascular coagulation
* Treatment with other investigational drugs within 14 days prior to first study treatment administration
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aptose Biosciences Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rafael Bejar, MD, PhD
Role: STUDY_DIRECTOR
Aptose Biosciences Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California Los Angeles
Los Angeles, California, United States
Pacific Cancer Care
Monterey, California, United States
Torrance Memorial Physician Network
Redondo Beach, California, United States
UCSD Moores Cancer Center
San Diego, California, United States
Sharp Clinical Oncology Research
San Diego, California, United States
Ridley-Tree Cancer Center
Santa Barbara, California, United States
St. Joseph Heritage Heathcare
Santa Rosa, California, United States
Rocky Mountain Cancer Centers
Aurora, Colorado, United States
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
Orlando Health
Orlando, Florida, United States
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, United States
University of Maryland, Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, United States
The Center for Cancer and Blood Disorders a division of American Oncology Partners of Maryland, PA
Bethesda, Maryland, United States
UMass Memorial Medical Center
Worcester, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Mayo Clinic Rochester
Rochester, Minnesota, United States
SCL Health, St. Vincent Frontier Cancer Center
Billings, Montana, United States
Morristown Medical Center
Morristown, New Jersey, United States
Manhattan Hematology Oncology
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Prisma Health - ITOR
Greenville, South Carolina, United States
Carolina Blood and Cancer Care Associates
Rock Hill, South Carolina, United States
Texas Oncology - Austin-Midtown
Austin, Texas, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
Texas Oncology - Fort Worth Cancer Center
Fort Worth, Texas, United States
University of Texas, M.D. Anderson Cancer Center
Houston, Texas, United States
University of Texas Health Science Center at San Antonio, Mays Cancer Center
San Antonio, Texas, United States
Texas Oncology - Tyler
Tyler, Texas, United States
Virginia Oncology Associates
Norfolk, Virginia, United States
Northwest Cancer Specialists, P.C. - Compass Oncology
Vancouver, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APTO-CG-806-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.